Type 2 Diabetes Clinical Trial
Official title:
Effect of Rebound Therapy on Metabolic Outcomes and Quality of Life in Nigerian Patients With Type 2 Diabetes
| Verified date | February 2016 |
| Source | University of KwaZulu |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Nigeria: Federal Ministry of Health |
| Study type | Interventional |
The purpose of this study was to investigate the effect of rebound exercise (mini trampoline jumping) on metabolic outcomes and quality of life in patients with Type 2 Diabetes.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | June 2015 |
| Est. primary completion date | June 2015 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 30 Years to 60 Years |
| Eligibility |
Inclusion Criteria: - 30- to 60-year-old male and female individuals; - A diagnosis of type 2 diabetes = 5 years; - Attendance at the Diabetes Outpatient Clinics of Aminu Kano Teaching Hospital and Murtala Muhammad Specialist Hospital in Kano, Northwestern Nigeria; - Self-ambulatory; - An inactive lifestyle over the last year. Exclusion Criteria: - A diagnosis of type 2 diabetes for more than 5 years; - Hypertension (systolic and diastolic blood pressure more than 140 and 90 mmHg, respectively) or treatment for hypertension; - Use of insulin therapy - Lower limb weakness and/or deformities with loss of protective sensation in the feet; - Back, shoulder or knee problems and/or joint instability; - History of coronary artery disease, retinopathy and nephropathy; - Myocardial infarction, cardiac or abdominal surgery within the previous 6 months; - History of fractures of the spine, hip, knee and/or ankle joints. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| University of KwaZulu | Aminu Kano Teaching Hospital |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Depressive symptoms as measured by the Beck's Depression Inventory | Score ranges from 0 to 63 with 0 to 13 being minimal and 29 to 63 being severe | 3 months | No |
| Primary | Glycated hemoglobin | Glycated hemoglobin was assessed using the mini-column ion-exchange chromatographic method and expressed in percentage | 3 months | No |
| Secondary | Fasting plasma glucose | Fasting plasma glucose (in molar concentration) was measured by glucose oxidase assay using a glucose analyzer | 3 months | No |
| Secondary | Fasting insulin | Fasting insulin (in gravimetric unit) was determined using a commercially available ELISA human insulin kit | 3 months | No |
| Secondary | High-density lipoprotein cholesterol | High-density lipoprotein cholesterol (in molar concentration) was enzymatically determined using commercial kits | 3 months | No |
| Secondary | Total cholesterol | Total cholesterol (in molar concentration) was enzymatically determined using commercial kits | 3 months | No |
| Secondary | Triglycerides | Triglycerides (in molar concentration) were enzymatically determined using commercial kits | 3 months | No |
| Secondary | Low-density lipoprotein cholesterol | Low-density lipoprotein cholesterol (in molar concentration) was estimated using the Friedewald formula. | 3 months | No |
| Secondary | Quality of life | The short-form 36 health questionnaire was used to assess participants' quality of life and expressed in percentage | 3 months | No |
| Secondary | Body mass | Body mass in kilograms was determined using a calibrated weighing scale | 3 months | No |
| Secondary | Height | Height in meters was determined using a stadiometer | 3 months | No |
| Secondary | Heart rate | Heart rate was measured in beats per minute using a calibrated electronic device | 3 months | No |
| Secondary | Respiratory rate | Respiratory rate (in cycles per minute) was measured by observing and counting the number of times the chest rose in one minute | 3 months | No |
| Secondary | Blood pressure | Blood pressure in millimeters of mercury (mmHg) was measured using a calibrated electronic device | 3 months | No |
| Secondary | Maximal oxygen consumption | Maximal oxygen consumption in milliliters per kilogram per minute (ml/kg/min) was obtained from exercise stress testing | 3 months | No |
| Secondary | Diabetes-related emotional distress as measured by the Problem Areas in Diabetes Scale | Diabetes-related emotional distress was expressed in percentage | 3 months | No |
| Secondary | Well-Being as measured by the World Health Organization-Well-Being Index | Participants' well-being was expressed in percentage | 3 months | No |
| Secondary | Treatment satisfaction as measured by the World Health Organization-Diabetes Treatment Satisfaction Questionnaire | Score ranges from 0 (very dissatisfied) to 36 (very satisfied) | 3 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
| Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
| Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
| Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
| Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
| Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
| Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
| Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
| Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
| Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
| Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
| Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
| Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |